What question did this study set out to answer?

To quantify the long-term public expenditure savings of TNF inhibitor biosimilars under Australia's PBS.

May 17, 2026Clinical Pharmacology & TherapeuticsOpen Access

Ten‐Year Public Expenditure Savings Associated with TNF Inhibitor Biosimilars under Australia's Pharmaceutical Benefits Scheme

View Full Paper

Ask AI

Bookmark

To quantify the long-term public expenditure savings of TNF inhibitor biosimilars under Australia's PBS.
Conducted a retrospective analysis using PBS Item Reports data from 2015 to 2025.
Estimated PBS cost savings associated with biosimilar listings of adalimumab, etanercept, and infliximab.
Constructed counterfactual scenarios to estimate expenditures without biosimilar entry.
Cumulative PBS savings of AU$562.3 million over the study period.
Etanercept biosimilar generated AU$341.5 million in savings (23.7% reduction).
Adalimumab biosimilars resulted in AU$195.3 million in savings (9.4% reduction), despite high use.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Retrospective expenditure analysis shows significant cost savings for TNF inhibitor biosimilars in Australia, indicating financial impact of biosimilar entry.

Cite This Study

Yiu et al. (2026) studied this question.

synapsesocial.com/papers/6a095b5d7880e6d24efe10ff https://doi.org/10.1002/cpt.70334

View Full Paper

Ask AI

Bookmark

Implication

Retrospective expenditure analysis shows significant cost savings for TNF inhibitor biosimilars in Australia, indicating financial impact of biosimilar entry.

Ten‐Year Public Expenditure Savings Associated with TNF Inhibitor Biosimilars under Australia's Pharmaceutical Benefits Scheme

Key Points

Discussion

Implication

Cite This Study

Ten‐Year Public Expenditure Savings Associated with TNF Inhibitor Biosimilars under Australia's Pharmaceutical Benefits Scheme

Key Points

Discussion

Implication

Cite This Study

Keep reading

Keep reading